Sign inJoin waitlistJoin the waitlist

Tim Greten

Co-Director, NCI CCR Liver Cancer Program · Clinical Center at the National Institutes of Health

Credentials: · ·

History

NCI CCR Liver Cancer Program · Clinical Center at the National Institutes of Health
Present
Clinical Center at the National Institutes of Health
Present
TGMB Section · Univ of Maryland Sch of Med
Present

Hematology and Medical Oncology
Internal Medicine
Christian Albrechts University

Research

Sorafenib in advanced hepatocellular carcinoma
New England Journal of Medicine · 2008 · 11,229 citations
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Science · 2017 · 5,443 citations
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Review · Nature Communications · 2016 · 2,341 citations

AD
Austin Duffy
37 papers
David Kleiner
24 papers
Changqing Xie
21 papers · 8 as a fellow
BW
Brad Wood
20 papers
William Figg
16 papers
Laurence Diggs
12 papers · 11 as a resident
Zachary Brown
12 papers · 12 as a resident
EL
Elliot Levy
11 papers
DH
Donna Hrones
10 papers
Jack McVey
10 papers · 10 as a resident
Justin McCallen
10 papers · 7 as a resident
Elizabeth Jaffee
9 papers

Grants

Analysis of Cancer-Related Immune Suppressor Mechanisms in Mice
National Cancer Institute · ZIA
Contact PI · $19.5M · Division of Basic Sciences - Nci
Center for Cell-Based Therapy - Cures
National Cancer Institute · ZIA
Contact PI · $6.5M · Division of Basic Sciences - Nci
Clinical Protocols for the Treatment of Gastrointestinal Cancer
National Cancer Institute · ZIA
Contact PI · $4.8M · Division of Basic Sciences - Nci
Immune Suppressor Mechanisms in Patients with GI Cancer
National Cancer Institute · ZIA
Contact PI · $2.2M · Division of Basic Sciences - Nci

Clinical trials

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Principal investigator · Withdrawn · Phase 2
National Cancer Institute (NCI)
2025
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Principal investigator · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2024–2042
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
2022
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
Principal investigator · Recruiting · Phase 1
National Cancer Institute (NCI)
2021–2027